Apply to trial NCT04665206

A few quick questions so the study team can decide if you might be a fit.

RecruitingDrug trial

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in patients with mesothelioma and/or metastatic solid tumors that are resistant to standard therapy or for which no effective standard therapy is available.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening